Alexandra Gerlach, Associate Editor

New recommendations from the American Stroke Association (ASA) emphasize the importance of healthy lifestyle habits and addressing health equity to reduce stroke risk.

The study was conducted on a small subgroup of Japanese patients with myelofibrosis.

Zolbetuximab is the first approved CLDN18.2-targeted treatment for gastric and gastroesophageal junction adenocarcinoma.

The tool can detect cell changes and mutations that drive resistance and relapse.

The researchers observe that the combination treatment results in higher serum levels compared with ezetimibe alone.

Cardiovascular diseases have a significant impact on brain health and function.

The real-world study results of ciltacabtagene autoleucel are comparable to data from the CARTITUDE-1 trial, emphasizing its efficacy and safety.

Survodutide is a glucagon/glucagon-like peptide-1 (GLP-1) receptor dual agonist that activates the glucagon and GLP-1 receptors to better control metabolic function.

Treosulfan showed superior benefits to busulfan as a conditioning regimen before allogenic hematopoietic stem cell transplantation (allo-HSCT).

Zodasiran is an RNA interference therapy targeting the ANGPTL3 loss-of-function mutation.

Pelabresib, a BET inhibitor, demonstrated meaningful reductions in spleen inflammation and anemia.

Research showed that children born via assisted reproductive technology were 36% more likely to develop heart defects.

High cholesterol levels are known risk factors for atherosclerotic cardiovascular disease.

Cholesin, a hormone found in the gut, may enhance the cholesterol-lowering capabilities of statins.

Fedratinib is an orally available, small molecule inhibitor of JAK-2 approved for treatment of myelofibrosis.

The findings may offer patients treatment options beyond symptom palliation.

Zanubrutinib demonstrated sustained responses in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Small molecule agents continue to be beneficial additions to multiple myeloma treatment, even with the development of T-cell redirected therapies.

Experts discuss emerging targets in the immunotherapy landscape and how to improve patient outcomes through innovative approaches.

Experts discuss immunotherapy advancements and challenges of resistance, efficacy, and toxicity in patient management.

Experts discuss current knowledge and future indications for immunotherapies and CAR T in early treatment lines.

INCA033989 is a monoclonal antibody that selectively targets mutant calreticulin oncogenic function.

The decision is based on positive results from the phase 3 LAURA trial.

Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma.

Early diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) may mitigate progression.

Researchers found that PF4/Cxcl4, a key driver of fibrosis, was up regulated on all proteomes.

Erin McConnell, PharmD, discusses the importance of effective cholesterol management for preventing heart disease.

The decision expands treatment options for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM).

Shifting from a vertical, isolated care model into a collaborative approach can improve the clinician and patient experience.